

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24

**Safety and efficacy of orally administered full-spectrum medicinal cannabis plant
extract 0.08% THC (NTI-164) in children with autism spectrum disorder:**

An open-label study

Dima El-Sukkari ¹, Kanan Sharma ¹, Bobbi Fleiss ², Dion L. Braganza ¹, Alison Crichton ^{3,4},
Michael C. Fahey ^{1*}

¹ Monash Children’s Hospital, Clayton, Victoria, Australia

² RMIT University, STEM College, Bundoora, Victoria, Australia

³ Department of Paediatrics, Monash University,

⁴ Developmental Paediatrics, Department of Paediatrics, Monash Children’s Hospital

***Corresponding author**

E-mail: Michael.Fahey@monash.edu

Funding This study was supported by Fenix Innovations.

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

25 **Abstract**

26 Autism spectrum disorder (ASD) is commonly associated with debilitating
27 comorbidities impacting the well-being of affected children and their families. Some children
28 with ASD experience behavioural difficulties that do not respond well to current medications
29 and may also experience unwanted side effects. Therefore, it is crucial to develop alternative,
30 safe and effective therapies. The improved understanding of the endocannabinoid system,
31 together with emerging evidence for the therapeutic effects of cannabis derivatives in
32 neurodevelopment disorders, has led to an exploration of their use in ASD.

33 This open-label study assessed the efficacy and safety of a novel oil-based full-
34 spectrum medicinal cannabis plant extract 0.08% THC (NTI-164) in treating 14 children with
35 ASD symptoms (13.4 years, range 10-17). Data on the safety profile of NTI-164 was collected
36 through biochemical analysis, vital signs, and parent and participant reports. The efficacy was
37 assessed through a dose-escalation protocol using a broad range of validated clinical
38 behavioural assessments and parent and child-reported questionnaires.

39 Following four weeks of treatment with NTI-164, 93% of participants demonstrated
40 significant overall improvement in ASD-related symptoms compared to baseline with transient
41 side effects that did not interfere with their general functioning. In addition, targeted
42 behavioural problems were rated as much improved or very much improved in 46% of the
43 treated patients. More than half of caregivers and children also reported decreased anxiety
44 symptoms.

45 The findings from this study suggest that NTI-164 is well-tolerated and safe, with
46 potential clinical benefits in improving disruptive behaviours and reducing anxiety in children
47 with ASD-related symptoms. Future longitudinal and well-controlled studies are warranted to
48 develop evidence-based clinical therapies and further evaluate the therapeutic benefit of full-

49 spectrum cannabis extracts in managing ASD core and associated comorbid symptoms in this
50 group of children.

51 **Trial registration number** ACTRN12621000760875

52

53

54 **Introduction**

55 Autism Spectrum Disorder (ASD) is a group of pervasive neurodevelopmental disorders
56 that appear in early childhood. These disorders are characterised by social functioning deficits,
57 restricted or repeated patterns of behaviour across the lifespan [1], and other comorbidities such
58 as intellectual disabilities, epilepsy, anxiety, hyperactivity, irritability, and sleep disturbances. [2,
59 3] These symptoms can significantly impact a person's daily functioning. [4, 5] Globally, the
60 prevalence of ASD is estimated to range from 0.4% to 1.7% [6]. In the last decade, the
61 prevalence rate of young children (under five years) diagnosed with ASD has increased by
62 6.7%, from 2.7 million in 1990 to 2.9 million in 2019 [7].

63 The families of children with ASD face a substantial financial burden, with recent
64 global estimates indicating 2834 EUR total costs for health-related services combined with
65 indirect societal costs over two months [8]. The estimated lifetime social cost in the US alone
66 was \$7 trillion for the last three decades (1990-2019) and is forecasted to increase to \$11-15
67 trillion in the following decade [9]. The continuing rise in ASD prevalence is further projected
68 to generate an enormous economic burden on US healthcare for decades and to reach an annual
69 cost estimate of \$5.54 trillion by 2060, with substantial potential yearly savings of \$1.9 trillion
70 through ASD prevention strategies [10]. Despite thorough investigation, no evidence supports
71 the effectiveness of pharmacological treatments in relieving some of the symptoms that cause
72 people with ASD distress. [11, 12]. However, these pharmacological treatments often result in

73 adverse side effects in children, with a notable variation in effectiveness between individuals
74 [13] and a lack of adherence [14]. The complexity of the ASD behavioural phenotype and its
75 aetiology resulting from the interaction of multiple genetic and environmental risk factors
76 further limits targeted interventions and the development of effective therapies [15, 16].
77 Therefore, to address core behaviours and co-morbid symptoms associated with ASD, targeted
78 therapeutic interventions are urgently needed.

79 The endocannabinoid system (ECS), consisting of cannabinoid receptors (CB1 and
80 CB2), endocannabinoids (endogenous bioactive ligands) and metabolic enzymes [17] presents
81 as a potential pharmacological target for developing therapeutics in the management of ASD
82 symptoms since it has a crucial role in modulation of neuronal plasticity during development
83 [18] and associated with social-emotional processes [19] which are impaired in ASD-related
84 phenotypes [20, 21]. The central endocannabinoid receptors CB1 and CB2 are expressed
85 mainly in sensory neurons and immune cells, including microglia [17]. The endogenous
86 cannabinoids are produced as required, activating presynaptic receptors to reduce calcium
87 uptake and inhibit the release of neurotransmitters, consequently influencing a broad range of
88 biological responses [22]. Alterations in ECS functionality have been reported in several
89 preclinical ASD models [23-25] and clinical studies [26-28], suggesting that ASD pathogenesis
90 likely involves dysregulation of the endocannabinoid signalling pathway. These findings
91 suggest that endocannabinoid anandamide (AEA) and its associated metabolic enzymes may
92 be a potential therapeutic target for ASD-related behavioural impairment. In animal studies,
93 treatment with inhibitors of the enzyme fatty acid amide hydrolase that degrades anandamide
94 resulted in increased AEA levels, restoring cognitive and social deficits in the ASD-related
95 knockout models [29-31].

96 The increased understanding of the ECS signalling concurrent with growing evidence
97 for the therapeutic effects of cannabis (*Cannabis sativa* L.) in neurodevelopment disorders has

98 been the catalyst for extensive research on the two most abundant active constituents Δ 9-
99 Tetrahydrocannabinol (THC) and Cannabidiol (CBD). During the last two decades, there has
100 been a surge in clinical trials of CBD owing to the absence of psychoactive effects and its
101 confirmed favourable safety profile in humans for the treatment of several neurological and
102 psychiatric disorders [32-34]. In addition, accumulating evidence from experimental and
103 animal model studies on the effect of CBD has demonstrated modulation of a broad range of
104 biological responses, including antidepressant [35], anti-inflammatory [36], antinociceptive
105 [37], anti-seizure [38], immunomodulatory [39] and neuroprotective activities [40].
106 Cannabinoids are generally well-tolerated, but evidence suggests that the risk of hepatotoxicity
107 may be increased when combined with other medications. This risk is usually low, dose-
108 dependent, and more likely to occur in individuals with a history of liver disease.[41] Rigorous
109 controlled clinical studies are needed to determine the efficacy and safety profile of
110 cannabinoids in children.

111 There is growing evidence that using CBD in combination with other plant compounds
112 found in cannabis as a full-spectrum botanical medicine could provide unique therapeutic
113 benefits, as suggested by anecdotal reports and emerging research in the field. [42] This effect,
114 known as the entourage effect, was initially proposed as a regulatory mechanism for the
115 endocannabinoid system, whereby multiple compounds enhance the activity of endogenous
116 cannabinoids. A recent meta-analysis of observational studies showed that twice as many
117 patients with treatment-resistant epilepsy improved when treated with an herbal formulation
118 that offered a better safety profile than isolated CBD product [46]. Furthermore, promising
119 evidence from preclinical cancer models supports the potential for the entourage effect of
120 botanical preparations to produce enhanced therapeutic responses than individual cannabinoids
121 [47-49]. Given that the current single molecule approach of individual phytocannabinoids
122 remains the predominant pharmaceutical development strategy [50], for complex diseases such

123 as ASD, multi-target strategies and botanical drug development may be an effective treatment
124 strategy.

125 Evidence from animal studies suggests that CBD positively affects various
126 physiological responses. However, there is limited evidence from clinical trials to support the
127 potential therapeutic benefits of this non-psychoactive phytocannabinoid for pediatric
128 neurodevelopmental disorders [51]. Only three randomised controlled studies have been
129 published on medicinal cannabis use in children with ASD; two were short-term [58, 59], and
130 the other only reported sleep outcomes [60]. Additionally, most studies on this topic are open-
131 label observational or retrospective design [52-57].

132 This single centre, phase I/II open-label study aimed to evaluate the efficacy and safety
133 of a novel oil-based full-spectrum medicinal cannabis plant extract with 0.08% THC (NTI-
134 164) in children with ASD over four weeks of daily treatment.

135

136

137 **Materials and methods**

138

139 **Study design and participants**

140 The study design was a single-centre open-label trial to evaluate the safety and efficacy
141 of a novel full-spectrum medicinal cannabis plant extract containing only 0.08% THC (NTI-
142 164) in children with ASD over four weeks of daily treatment. The trial enrolled 18 eligible
143 male and female paediatric patients aged 8-17 with Level 2 or 3 ASD based on the Autism

144 Diagnostic Observational Schedule (ADOS-2) criteria [61] between 4 February 2022 and 8
145 September 2022.

146 This study was approved by the Monash Health Human Research Ethics Committee
147 (RES-21-0000-177A) and registered with the Australian and New Zealand Clinical Trial
148 Registry (Trial ID: ACTRN12621000760875).

149

150 **Study objectives**

151 The primary objective was to evaluate the safety and tolerance of NTI-164 in children
152 with ASD throughout the trial. In addition to assessment questionnaires, safety data were
153 collected through laboratory tests, including full blood examination, liver and renal function
154 tests performed at screening and at the beginning of week five during hospital visits. The
155 secondary objective was to assess the efficacy of NTI-164 in treating ASD-associated
156 symptoms. Efficacy data were collected through physician, parent (or caregiver) and school-
157 aged participant-reported questionnaires at two designated time points. This study explored the
158 effect of NTI-164 on core behavioural symptoms of children with ASD and associated
159 symptoms, including irritability, hyperactivity, mood, anxiety, sleep disorders and self-
160 stimulation.

161

162 **Pharmacological Intervention**

163 The chemical composition profile of the investigational product NTI-164 consisted of
164 62% Cannabidiolic Acid (CBDA), 14% Cannabidiol (CBD), 0.44% Cannabigerolic Acid
165 (CBGA), 0.06% Cannabidivarin (CBDV) and 0.08% Tetrahydrocannabinol (THC). The

166 investigational product was provided and dispensed in a glass jar as a 53 mg/mL oil-based
167 solution ready for self-administration at home. During the initial hospital visit (baseline), the
168 participants received the packaged investigational product with instructions. Participants were
169 also given access to a web app (Caspio Participant Portal) to record daily drug administration.

170 Several lines of evidence from controlled trials have shown the effectiveness of CBD
171 at a dose of 20 mg/kg in managing seizures [62-64]. Therefore, this dose was used in the current
172 study, with participants starting treatment on a daily dose of 5mg/kg of NTI-164 at baseline.
173 To minimise the risk of undesired side effects, the dose was increased by 5mg/kg weekly to
174 reach the maximum tolerated daily dose or 20 mg/kg daily. The daily dose was calculated by
175 multiplying the dosage by each patient's weight and then dividing by the concentration of
176 CBDA in the oil (53mg/mL). This provided a total daily volume in mL divided into twice daily
177 doses. Protocol adherence was assessed by the accountability of returned investigational
178 product and packaging at the end of the four weeks.

179

180 **Outcome measures**

181 **Primary outcome measure**

182 The primary endpoint was safety and tolerability of NTI-164 treatment as determined
183 by monitoring and assessment through standard laboratory tests of full blood examination, liver
184 and renal function tests, as well as vital signs in addition to physician and parent (or caregiver)
185 reported questionnaires completed at baseline and after completion of 4 weeks of treatment.

186 Adverse events were assessed and evaluated by designated study staff through
187 discussions with the participant at the scheduled study visit after the end of four weeks, as well
188 as through phone contacts and clinically significant laboratory results. Whenever an adverse

189 event was reported during treatment at home, the Principal Investigator was notified
190 immediately via the online portal. The Principal Investigator or a designated study staff
191 member promptly followed all adverse events. Documentation of adverse events included
192 details of the event, dates and times, severity, duration and possible relationship to the
193 investigational product.

194 **Secondary outcome measure**

195 The efficacy assessments included the administration of both quantitative and
196 qualitative ASD-related questionnaires, with the first four scales described below completed
197 by both the caregiver and clinician. The selected questionnaires were specific to various co-
198 morbidities associated with autism spectrum disorder. The purpose was to evaluate the impact
199 of NTI-164 on symptoms associated with autism spectrum disorder. All scales were
200 administered at baseline (week 1) and post-baseline (week 5).

201 1. Clinical Global Impression of Improvement for the Caregiver (CGI-I-Ca) [65]: This is a 7-
202 point scale measuring symptom change from baseline.

203 2. Clinical Global Impression of Improvement for the Clinician (CGI-I-C) [65]: This is a 7-
204 point scale measuring symptom change from baseline.

205 3. Caregiver Global Impression of Change (CGI-C) Target Behaviour [65]: Reflects clinician's
206 impression of behaviour change on a 7-point scale ranging from 1=not at all to 7=very severe
207 problem.

208 4. Clinical Global Impression of Change in Attention (CGI-CA) [65]: Reflects clinician's
209 impression of change in attention on a 7-point scale ranging from 1=not at all to 7=very severe
210 problem.

211 5. Clinical Global Impression of Severity of Illness (CGI-S) [65]: Reflects clinician's
212 impression of severity of illness on a 7-point scale ranging from 1=not at all to 7=among the
213 most extremely ill.

214 6. Anxiety Scale for Children - autism spectrum disorder – Parent Version (ASC-ASD-P) [66]:
215 Parent/Caregiver form was developed to detect anxiety symptoms in youth with ASD. They
216 are composed of four subscales: Performance Anxiety, Uncertainty, Anxious Arousal, and
217 Separation Anxiety. Items are rated on a 4-point scale (0=never and 3=always). Subscales sum
218 to equal a total score.

219 7. Anxiety Scale for Children - autism spectrum disorder – Child Version (ASC-ASD-C) [66]::
220 Child form developed to detect symptoms of anxiety in youth with ASD. Composed of the four
221 Subscales: Performance Anxiety, Uncertainty, Anxious Arousal, and Separation Anxiety.
222 Items are rated on a 4-point scale (0=never and 3=always). Subscales sum to equal a total
223 anxiety score, with lower scores indicating a decreased level of anxiousness. The total score
224 ranged from 6 to 55 and 3 to 50 out of a possible maximum score of 72 for the ASC-ASD-P
225 and ASC-ASD-C version, respectively.

226 8. Sleep Disturbance Scale for Children (SDSC) [67]: Includes the six subscales of Disorders
227 of Initiating and Maintaining Sleep, Sleep Breathing Disorders, Disorders of Arousal, Sleep
228 Wake Transition Disorders, Disorders of Excessive Somnolence, and Sleep Hyperhydrosis.
229 Items are rated on a 5-point scale where 1=never and 5=always (daily). Subscale scores sum to
230 equal a total sleep score, with a higher score reflecting more sleep-related problems.

231

232 **Study procedures**

233 The study schedule of procedures and assessments is presented in Table 1. Participants
234 were recruited through Monash Children’s Hospital (MCH) in Melbourne, Australia. Potential
235 participants attended a screening visit for assessment based on study selection criteria (See
236 Supplementary information, File 1) and were provided with the Participant Information Sheet
237 and Consent Form. After obtaining written informed consent from caregivers, eligible
238 participants underwent a physical assessment, including vital signs, anthropometric
239 measurements, full blood examination, liver and renal function tests as part of the screening
240 process. In case of restrained compliance with blood sample collection, analgesia with nitrous
241 oxide was administered by a trained staff member. At this visit, a parent survey was obtained
242 concerning the medical and family history of the participating child, including current
243 attendance at specific programs or health service utilisation.

244 **Table 1.** Study schedule of procedures and assessments for the 28 day open-label trial.

Assessments	Screening	Visit 1/ Week 1	Visit 2 / Week 5
Day	-14 to -1	1	29
CGI-I-Ca Baseline		X	
CGI-I-Ca Post-baseline			X
CGI-I-C Baseline		X	
CGI-I-C Post-baseline			X
CGI-C Baseline		X	
CGI-C Post-baseline			X
CGI-CA Baseline		X	
CGI-CA Post-baseline			X
CGI-S		X	X

Assessments	Screening	Visit 1/ Week 1	Visit 2 / Week 5
SDSC		X	X
ASC-ASD-P		X	X
ASC-ASD-C		X	X
Parent survey	X		
Medical history	X		
Concomitant medications	X	X	X
Physical examination (including vital signs)	X	X	X
Weight measurement	X	X	X
Height measurement	X		
FBE	X		X
LFT	X		X
UEC	X		X
Dispense study medication		X	X
Collection returned IP			X
Drug administration		X-----daily-----X	
Caspio Participant Portal (web app)		X-----daily-----X	
Caspio Physician Portal (web app)	X	X	X
Evaluation measures		X	X
Safety outcome measure		X	X

Assessments	Screening	Visit 1/ Week 1	Visit 2 / Week 5
Adverse events		X	X
Accountability		X	X

245 **Abbreviations** ASC-ASD-C: Anxiety Scale for Children - Autism Spectrum Disorder; ASC-ASD-P: Anxiety
246 Scale for Children - Autism Spectrum Disorder - Parent Versions; CGI-I-Ca: Clinical Global Impression of
247 Improvement for the Caregiver; CGI-I-C: Clinical Global Impression of Improvement for the Clinician; CGI-C:
248 Caregiver Global Impression of Change; CGI-CA: Caregiver Global Impression of Change in Attention; CG-S:
249 Clinical Global Impression–Severity; SDSC: Sleep Disturbance Scale for Children.

250 At the first visit in week 1 (baseline), participants completed all the required
251 questionnaires and the first daily dose of 5mg/kg of the investigational product NTI-164 was
252 administered. The participant was monitored for 2 hours for any immediate adverse events.
253 Participants who did not report any adverse events were dispensed with NTI-164 for four weeks
254 and instructed to administer the daily volume orally over two doses. Instructions were provided
255 on administering increasing the dose of the product to a maximum of 20mg/kg/day from home.
256 Participants were also trained to use the study web app (Caspio Participant Portal) to record
257 drug administrations, report adverse events, and complete questionnaires from home.

258 Once the four-week treatment was completed, at the start of the week 5 visit (post-
259 baseline), participants underwent the same set of laboratory tests and physical assessments as
260 before and completed all specified post-baseline questionnaires. To ensure adherence to study
261 protocol and accountability, returned product and packaging were collected and recorded at
262 this visit.

263

264 **Statistical analysis**

265 The safety and tolerability were assessed by recording the frequency and severity of
266 reported adverse events by all treated participants. The distribution was analysed using patient
267 demographics, laboratory values and vital signs. Given the small sample size of this study,
268 descriptive statistical analyses of the mean score, mean change, and Standard Deviation (SD)
269 were performed on quantifiable outcome measures. The Wilcoxon Signed-Rank Test and the
270 Paired t-test were used to assess the statistical significance of the analysed data sets. The final
271 statistical analysis included all participants completing the initial four week treatment phase.
272 The CGI-S scale was used to analyse the therapeutic effect of NTI-164 and its changes to the
273 severity of illness. The ASC-ASD-C and ASC-ASD-P questionnaires were used to assess
274 anxiety across four sub-domains, and the SDSC was used to assess changes to sleep from
275 baseline and at the end of the 4 weeks. Clinical Global Impression scales were used to analyse
276 efficacy by measuring symptom change from baseline. Each CGI survey uses the same 7-point
277 scale to measure symptom change from baseline: Very much improved, Much improved,
278 Minimally improved, No change, Minimally worse, Much worse and Very much worse.

279

280 **Results**

281

282 **Participant characteristics**

283 Fourteen of the 18 participants enrolled in the study completed the full treatment. One
284 patient withdrew before treatment began, and three patients discontinued during treatment.
285 Most of the treated patients were male (9/14), Caucasian (12/14), and had an average age of
286 13.4 years (ranging from 10-17 years). All active patients were diagnosed with ASD Level 2/3
287 and were evaluated at baseline as "Mildly ill" (4 patients), "Moderately ill" (4 patients),

288 "Markedly ill" (3 patients), or "Severely ill" (3 patients), according to the CGI-Severity of
289 Illness scale. The average daily dose for treated patients was 16.7 mg/kg/day. About 64% of
290 patients could tolerate the maximum dose of 20 mg/kg/day, while 36% tolerated a maximum
291 daily dose ranging between 6 mg/kg/day and 19 mg/kg/day.

292

293 **Safety and tolerability**

294 Eight participants experienced ten mild to moderate adverse events, totalling 17 adverse
295 reports during treatment. One participant discontinued treatment. The most frequent side-effect
296 was gastrointestinal symptoms reported by a third of participants (36%). None of these side
297 effects were severe enough to significantly interfere with the patient's functioning. Most
298 patients were advised to rest to treat these transient adverse effects (Table 2). No serious
299 adverse events or deaths related to the investigational drug were reported during the study. The
300 safety data indicated that NTI-164 at 5, 10, 15 and 20 mg/kg administered in two daily doses
301 is safe and well-tolerated in this study population. Laboratory values provide further safety
302 support. No changes were observed in patients' full blood examination, liver function or kidney
303 function tests (Table 3). Also, no changes were observed to the vital signs of active patients
304 during treatment, further corroborating that NTI-164 was well-tolerated.

305 **Table 2.** Reported adverse events during the trial.*

Adverse Event	Total No. of Reports	Frequency (%)	Treatment
Abdominal pain	3	14%	Rest
Lack/loss of appetite	3	14%	None
Diarrhoea	2	9%	None
Vomiting	2	9%	None

Lethargy	2	9%	Rest
Hypoglycaemia	1	5%	None
Rashes**	1	5%	Zyrtec for itchiness
Itchiness without rash	1	5%	Warm shower
Sore Throat	1	5%	Rest
Upper Respiratory Tract Infection	1	5%	Treated by doctor

306 * Two participants were excluded as one had ingrown nail infection and one had knee
307 surgery

308 ** This participant discontinued during the treatment and did not complete the study

309

310 **Table 3.** Evaluation of clinical laboratory parameters (n=12) at timepoint 1 (screening visit)
311 and timepoint 2 (start of week 5).

Parameter	Timepoint 1			Timepoint 2			Median Change
	Mean	Minimu m	Maxim um	Mean	Minimu m	Maximu m	
Sodium	139	136	142	139	137	141	-1
Potassium	4.3	3.8	4.8	4.4	3.7	4.8	0
Chloride	104	102	108	104	101	106	1
Bicarbonat e	25	19	29	25	22	30	0
Urea	4.6	3.1	6.1	4.1	2.6	5.9	0.2

Creatinine	47	35	68	50	36	73	3
Glucose	4.9	3.3	6.3	4.5	2	7.1	-0.1
ALP	287	101	438	280	82	424	-23
GGT	17	11	25	15	8	29	-0.5
ALT	24	5	57	26	6	48	0
Total	11	4	40	9	4	14	0
Bilirubin							
Haemoglobin	133	115	147	133	119	144	2
RBC	4.69	4.1	5.34	4.74	4.36	5.11	0.11
MCV	83	75	90	84	77	90	1.5
MCH	32.4	25.2	86	28.2	25.5	30.8	0.3
MCHC	342	331	349	337	330	348	2
RDW	13.5	12.4	16.7	13.7	12.6	16.9	0.3
WCC	7.6	4.8	14.6	7.0	4.4	11.4	-1
Neutrophils	3.94	1.7	8.69	3.47	1.79	4.7	-0.66
Lymphocytes	2.66	1.45	6.16	2.54	1.15	4.73	-0.035
Monocytes	0.54	0.31	0.79	0.55	0.35	1.05	-0.06
Eosinophils	0.45	0.1	1.24	0.41	0.03	1.14	-0.05
Basophils	0.05	0	0.09	0.06	0	0.1	0.02
Platelets	294	190	413	301	214	422	-13.5

313 **Abbreviations.** ALP : Alkaline Phosphatase; ALT : Alanine Transaminase; GGT: Gamma-
314 Glutamyl Transferase; MCH: Mean Corpuscular Haemoglobin; MCHC: Mean Corpuscular
315 Haemoglobin Concentration; MCV: Mean Corpuscular Volume; RBC: Red blood cell;
316 RDW: Red Cell Distribution Width; WCC: White Cell Count.

317

318 **Analysis of therapeutic efficacy**

319 **Clinical Global Impression-Severity (CGI-S)**

320 The Clinical Global Impression-Severity (CGI-S) scale was used to assess global
321 improvement, the severity of illness, and the efficacy index based on drug effect only (Table
322 4). Of the 14 treated patients, 13 (93%) showed symptomatic improvement. 64% of these
323 patients showed a global improvement of ‘Much improved’, 29% showed ‘Minimally
324 improved’, and only one patient (7%) had ‘No change’ (Figure 1).

325 **Fig 1. Clinical Global Impression – Global Improvement.**

326 **Table 4.** Symptom change scores for each Clinical Global Impression (CGI) scale.

CGI Assessment	Symptom Change from Baseline			
	1. Very much improved	2. Much improved	3. Minimally improved	4. No change
CGI of Severity of Illness (CGI-S)	0	9 (64%)	4 (29%)	1 (7%)
CGI of Improvement for the Caregiver	1 (7%)	7 (50%)	4 (29%)	2 (14%)

(CGI-I-Ca)

CGI of Improvement for the	1 (7%)	4 (29%)	7 (50%)	2 (14%)
-----------------------------------	--------	---------	---------	---------

Clinician

(CGI-I-C)

CGI of Change in Target	2 (14%)	4 (29%)	3 (21%)	5 (36%)
--------------------------------	---------	---------	---------	---------

Behaviour

(CGI-C)

CGI of Change in Attention	0	3 (21%)	4 (29%)	7 (50%)
-----------------------------------	---	---------	---------	---------

(CGI-CA)

327

328 At baseline, the average rating for the severity of illness was 4.4, which was reduced to
 329 an average rating of 3.6 after 28 days of NTI-164 treatment (Figure 2). The mean difference of
 330 CGI-S between 28 days of treatment and baseline was -0.714 (95% CI: -1.332, -0.097,
 331 $p=0.027$), with the Wilcoxon Signed-Rank Test statistic showing a significant difference of -
 332 15 ($p=0.047$).

333 **Fig 2. Clinical Global Impression – Severity of Illness.**

334 At the end of the study, 14% of active patients receiving daily treatment with NTI-164
 335 demonstrated the second highest possible efficacy index of 2, indicating marked therapeutic
 336 effects with side effects that did not significantly interfere with functioning. Clinicians rated
 337 NTI-164 to have a moderate therapeutic effect (efficacy index of 5 or 6) in 72% of treated
 338 patients, with half having no side effects and the other half having side effects that did not
 339 significantly interfere with functioning. A minimal therapeutic effect (efficacy index of 9) was
 340 observed in 7%, and an unchanged therapeutic effect (efficacy index of 13) in just one
 341 participant (Figure 3).

342 **Fig 3. Clinical Global Impression - Therapeutic Effect after 28 days of treatment.**

343

344 **Anxiety symptoms**

345 To measure anxiety symptoms in treated participants with ASD, the Anxiety Scale for
 346 Children, both -Parent and -Child versions (ASC-ASD) were used. The mean scores, Wilcoxon
 347 Signed-Rank test, and corresponding *p* values for both ASC-ASD-P and ASC-ASD-C versions
 348 are summarised and reported in Table 5. The total score of the Anxiety Scale for Children was
 349 reduced in more than half of both parents (62%) and children (54%) scales after four weeks of
 350 treatment. During the same period, nearly a quarter of parents (23%) and a third of children
 351 (36%) reported increased levels of anxiousness, while 15% and 9% of parents and children
 352 reported no change, respectively. The mean change for the total score of the ASC-ASD parent
 353 version was significantly reduced by 14% ($p=0.0414$), while the child version of the scale was
 354 non-significantly reduced by 6.8% after four weeks of treatment. The most frequently endorsed
 355 items on the ASC-ASD-P and ASC-ASD-C were from the Uncertainty (mean change 15.6%)
 356 and Separation Anxiety (25.4%) subscales post-treatment, respectively (Table 5).

357 **Table 5.** Anxiety assessment for Children. Results are expressed as Mean ± SD

Assessment	Baseline	Week 5	Mean change	Wilcoxon signed rank test (<i>P</i> value)
<i>Anxiety Scale for Children – Parent Version (ASD-ASC-P) n=11</i>				
Total ASC-ASD	31.5± 14.7	27.1± 12.9	-4.4	47.5 (0.0414)
Performance Anxiety	7.5± 4.4	6.5± 3.7	-1.0	25.5 (0.0474)
Anxiety Arousal	4.0± 3.9	3.9± 3.2	-0.1	15.0 (0.865)

Separation Anxiety	5.3± 4.1	4.9± 4.0	-0.4	17.5 (0.139)
Uncertainty	14.1± 5.8	11.9± 4.4	-2.2	47.0 (0.0459)
<i>Anxiety Scale for Children – Child Version (ASD-ASC-C) n=9</i>				
Total ASC-ASD	30.9± 10.1	28.8± 13.3	-2.1	33.0 (0.213)
Performance Anxiety	6.6± 3.9	6.1± 3.3	-0.5	21.0 (0.206)
Anxiety Arousal	4.3± 3.7	5.4± 3.1	1.1	11.5 (0.360)
Separation Anxiety	6.7± 3.6	5.0± 4.4	-1.7	37.0 (0.0834)
Uncertainty	13.3± 4.9	12.2± 5.5	-1.1	26.0 (0.258)

358

359 **Sleep quality and sleep disturbances**

360 To assess changes to sleep quality, the SDSC questionnaire was used. Of the 14 study
 361 participants, 11 children completed sleep assessment before and after 28 days of treatment.
 362 Although the total sleep score decreased from baseline to post-treatment, it was not statistically
 363 significant. The scores for all sleep outcomes except Disorders of excessive somnolence
 364 improved non-significantly from baseline to post-treatment (Table 6).

365 **Table 6** Sleep Disturbances Scale for Children (SDSC). Results are expressed as Mean ± SD

Sleep Domains	Baseline	Week 5	Mean difference	Wilcoxon signed-rank test (p value)
Total Score (n=11)	50.5± 17.1	48.4± 13.4	-2.0	29 (0.721)
Disorder of initiating & maintaining sleep	17.6± 6.9	16.4± 6.3	-1.2	24.5 (0.811)

Sleep breathing disorders	6.0 ± 3.0	5.5± 2.3	-0.5	16 (0.234)
Disorders of arousal	4.0± 1.6	3.9± 1.2	-0.1	3 (1)
Sleep-wake transition disorders	11.9± 4.4	11.2± 3.3	-0.7	15 (0.343)
Disorders of excessive somnolence	8.3± 3.3	9.1± 3.7	0.8	13 (0.481)
Sleep hyperhydrosis	2.7± 1.2	2.4± 0.9	-0.3	5 (0.285)

366

367

368 Discussion

369 The current pharmacological and behavioural interventions are limited in treating a
370 considerable portion of children with ASD-related symptoms due to a lack of efficacy or
371 adverse side effects that interfere with daily functioning. Therefore, there is an urgent need for
372 a more concerted effort in clinical research to develop effective and safer therapies for
373 addressing ASD associated comorbid symptoms. While the available evidence from controlled
374 studies on the role of medicinal *Cannabis sativa* in the management of children with ASD is
375 limited, a large body of evidence from preclinical studies has demonstrated the positive effects
376 of cannabinoids in the modulation of a wide range of biological responses in particular
377 neurodevelopmental processes. Furthermore, emerging evidence from recent observational
378 studies [53-55, 57] has indicated that a synergistic and entourage pharmacological effect of
379 *Cannabis sativa* derivatives can contribute to improved ASD-related symptoms and
380 comorbidities in children. Therefore, this study sought evidence for the safety and efficacy of
381 NTI-164, a full spectrum botanical product, per the entourage effect in managing ASD
382 comorbid symptoms in paediatric patients. The findings demonstrate that NTI-164 is safe and

383 well-tolerated in children up to 20 mg/kg daily dose with transient side effects that did not
384 significantly interfere with the general functioning of treated patients.

385 Furthermore, NTI-164 exhibited statistically significant efficacy in improving ASD
386 core and associated symptoms after four weeks of treatment. In particular, following NTI-164
387 treatment, targeted behavioural problems were much improved or very much improved in
388 nearly half of the patients. More than half of caregivers and children also reported consistent
389 improvements in the anxiety level of participants. Despite the limited sample size with
390 completed sleep data, the overall direction of change indicated improved sleep outcomes and
391 warrants further longitudinal evaluation. Based on these promising findings, we have initiated
392 an extended treatment open-label trial for 57 weeks to assess long-term NTI-164 safety and
393 efficacy in children and adolescents with ASD and related comorbidities.

394

395 **Impact of full-spectrum cannabis extract on ASD core symptoms**

396 The safety profile and tolerability of NTI-164 were favourable in the patients who
397 completed treatment consistent with previous clinical studies that used whole plant medicinal
398 cannabis extract to treat children and adolescents with ASD-related symptoms [52-58]. The
399 most frequent side-effect in our cohort was related to gastrointestinal symptoms, which were
400 transient and improved with rest by the end of the treatment phase. However, the majority of
401 clinical studies using full-spectrum cannabis extract for the treatment of children with ASD
402 reported mild or transient adverse events frequently related to sleep disturbances [52-55, 58,
403 59], anxiety or irritability symptoms [52, 55, 57, 58] which were absent in our cohort. This
404 might be due to different strains with variable composition of phytocannabinoids and higher
405 doses of THC than our full-spectrum medical cannabis extract with negligible THC (0.08%).
406 Alternatively, side-effects not observed in our study might be due to other studies, including

407 primarily children diagnosed with severe ASD, since sleep disturbances have been reported as
408 a side-effect of isolated CBD treatment in children with severe behavioural problems [68]. In
409 addition, several studies have found that the severity of ASD core symptoms is associated with
410 the severity of sleep disturbances in younger children [60, 69, 70]. Compared to other clinical
411 studies that included children as young as four years old, our active patients were much older
412 (10-17 years). The effect of different compositions of phytocannabinoids and THC levels in
413 full-spectrum extracts on the severity of ASD symptoms in younger children, therefore,
414 requires further investigation.

415 This is the first study of full-spectrum cannabis extract treatment in children with ASD
416 to report subjective measures of adverse events and objective measures of biochemical analysis
417 and vital signs following treatment. In a prospective cohort study of biochemical safety analysis
418 of an oil-based full-spectrum cannabis product, all parameters were within the normal range in
419 children with ASD after three months of treatment [71]. However, this study did not report an
420 evaluation of adverse events or vital signs following treatment. Notably, a recent randomised
421 controlled feasibility study reported no significant abnormal biochemical test results after eight
422 weeks of therapy with isolated CBD in children with severe behavioural problems and
423 intellectual disability [68].

424 In our study, overall daily treatment with NTI-164 for four weeks significantly
425 improved symptoms in 93% of active patients, with nearly two-thirds of children rated by
426 clinicians to exhibit moderate effects following treatment. Similarly, several cohort studies in
427 children using full-spectrum products have demonstrated significant overall improvement in
428 ASD symptoms reported by parents [52-54, 56] and clinicians [55, 57]. Specifically, we found
429 that almost half of treated children with ASD showed reduced disruptive behaviour consistent
430 with other studies that have demonstrated improvement in behavioural problems ranging from
431 32% to 90%, including adaptive behaviours, self-injury and hyperactivity [53, 57, 59]. Social

432 interaction and communication have also significantly improved following treatment with full-
433 spectrum cannabis extract in children with ASD-related symptoms [52, 55-57]. In addition,
434 two randomised controlled trials have shown that cannabinoid treatment, compared to placebo
435 in children, was safe with acceptable tolerability and effective at reducing ASD-associated
436 disruptive behaviours [58, 59]. However, compared to pure cannabinoids, there was no
437 apparent difference with improvements observed for treatment with whole-plant extract after
438 12 weeks. The clinical benefits of the entourage effects of our cannabis strain compared to
439 purified cannabinoids remain to be further explored in longitudinal controlled studies.

440

441 **Impact of full-spectrum cannabis extract on ASD-related comorbidities**

442 In addition to improvements in behavioural outcomes, a recent systematic review of the
443 evidence for medicinal cannabis in ASD treatment found benefits for a broad range of
444 comorbidities, including cognition, anxiety and sleep disturbances in adults and children [72].
445 Consistent with previous studies [52-54], we also found that after four weeks of treatment with
446 full-spectrum cannabis extract, anxiety symptoms were reduced in more than half of our cohort
447 based on both parent and children reported anxiety questionnaires. In particular, the parent-
448 rated total scores and the performance anxiety and uncertainty subscales significantly improved
449 for children with ASD. However, the magnitude of improvement on child-rated outcome
450 measures did not reach statistical significance despite the direction of change, suggesting
451 reduced anxiety symptoms in half of the treated patients. This rating discrepancy might be due
452 to differences in perceptions of anxiety for children with ASD and their parents with the
453 severity of ASD symptoms reportedly contribute to the disparity in parent-child anxiety rating
454 where higher severity levels were shown to be associated with the tendency for parent ratings
455 to exceed child anxiety rating [73]. Nevertheless, this finding highlights the clinical implication

456 of self-report rating to inform areas of concern for continued assessment of anxiety symptoms
457 in children with ASD.

458 While previous prospective cohort studies have reported treatment with whole plant
459 cannabis extract of various strains significantly improved sleep outcomes in children with ASD
460 [53-55], a recent randomised controlled trial did not find any difference between cannabinoid
461 treatment and placebo in sleep parameters after 12 weeks [60]. We also did not find significant
462 improvement in any of the sleep domains as measured by a validated sleep questionnaire. These
463 inconsistencies could be due to differences in treated participant characteristics, especially
464 level of ASD severity, age, instruments used to measure sleep or strain of cannabis with various
465 phytocannabinoid composition. In addition, since the previous studies that reported improved
466 sleep outcomes were over several months, this may indicate the need for a longer period before
467 any benefit in sleep quality can be observed from treatment with cannabinoid extract.

468 These findings support the safety and efficacy of full-spectrum products and promising
469 entourage effects of cannabinoids in treating children with ASD-related symptoms.

470

471 **Limitations**

472 There were several limitations in this study. Since our study was an open-label design
473 to collect preliminary data on the safety and efficacy of NTI-164 treatment of symptoms in
474 children with ASD, no control group was included. However, the addition of objective
475 measures of vital signs and biochemical analysis to subjective reports of adverse events further
476 strengthened the NTI-164 safety profile in treated children with ASD. Nevertheless, further
477 research for long-term evaluation of safety data of NTI-164 botanical product for the treatment

478 of children with ASD symptoms, especially in terms of interaction with concomitant
479 medications, is needed.

480 Given that the sample size was small, evaluation of the impact of NTI-164 treatment
481 on subgroups of children with various ASD severity was not possible. Although data was
482 collected on concomitant medications prescribed for ASD-related comorbidities, this study was
483 not powered to determine the impact of chronic medication on treatment response. Also, we
484 only used subjective measures of sleep outcomes, and future studies should include actigraphy
485 or polysomnography together with sleep diaries as objective measurements of sleep quality.

486

487

488 **Conclusions**

489 This open-label study provided preliminary efficacy and safety data on a novel botanical
490 formulation of phytocannabinoids in treating symptoms in children with ASD and associated
491 comorbidities. Results indicate that NTI-164 is safe and well-tolerated, with significant
492 efficacy in improving disruptive behaviours and reducing anxiety in this Pediatric cohort. The
493 findings of this study further contribute to the accumulating evidence in favour of whole plant
494 cannabis extracts, with most participants reporting a clinically meaningful change in ASD-
495 related symptoms and associated anxiety. Despite the small sample size, objective safety
496 analysis together with converged evidence from standardised clinician, parent and child-
497 reported questionnaires with respect to overall improvement strengthen the evidence for the
498 benefit of full-spectrum cannabis extract in the treatment of children with ASD-related
499 symptoms. Furthermore, these results are consistent with other prospective cohort studies of

500 full-spectrum cannabis extract and support further evaluation of the clinical benefits of whole
501 plant extracts in rigorous placebo-controlled trials of longer duration in this patient population.

502

503

504 **References**

505 1. American Psychiatric Association. Diagnostic and statistical manual of mental
506 disorders: American Psychiatric Publishing; 2013.

507 2. Lord C, Brugha TS, Charman T, Cusack J, Dumas G, Frazier T, et al. Autism
508 spectrum disorder. *Nat Rev Dis Primers*. 2020;6(1):1-23.

509 3. Simonoff E, Pickles A, Charman T, Chandler S, Loucas T, Baird G. Psychiatric
510 disorders in children with autism spectrum disorders: prevalence, comorbidity, and associated
511 factors in a population-derived sample. *J Am Acad Child Adolesc Psychiatry*.
512 2008;47(8):921-9.

513 4. Evers K, Maljaars J, Schepens H, Vanaken GJ, Noens I. Conceptualization of quality
514 of life in autistic individuals. *Dev Med Child Neurol*. 2022;64(8):950-6.

515 5. Van Heijst BF, Geurts HM. Quality of life in autism across the lifespan: A meta-
516 analysis. *Autism*. 2015;19(2):158-67.

517 6. Salari N, Rasoulpoor S, Rasoulpoor S, Shohaimi S, Jafarpour S, Abdoli N, et al. The
518 global prevalence of autism spectrum disorder: a comprehensive systematic review and meta-
519 analysis. *Ital J Pediatr* 2022;48(1):1-16.

- 520 7. Kang L, Liu J, Liu Y, Liang W, Yang F, Liu M. Global, regional, and national disease
521 burden of autism spectrum disorder among children under 5 years from 1990 to 2019: An
522 analysis for the Global Burden of Disease 2019 Study. *Asian Journal of Psychiatry*.
523 2023;79:103359. doi: <https://doi.org/10.1016/j.ajp.2022.103359>.
- 524 8. Bieleninik Ł, Gold C. Estimating components and costs of standard care for children
525 with autism spectrum disorder in Europe from a large international sample. *Brain Sci*.
526 2021;11(3):340.
- 527 9. Cakir J, Frye RE, Walker SJ. The lifetime social cost of autism: 1990–2029. *Res*
528 *Autism Spectr Disord*. 2020;72:101502. doi: 10.1016/j.rasd.2019.101502.
- 529 10. Blaxill M, Rogers T, Nevison C. Autism Tsunami: the Impact of Rising Prevalence on
530 the Societal Cost of Autism in the United States. *J Autism Dev Disord*. 2022;52(6):2627-43.
531 doi: 10.1007/s10803-021-05120-7.
- 532 11. Aishworiya R, Valica T, Hagerman R, Restrepo B. An Update on
533 Psychopharmacological Treatment of Autism Spectrum Disorder. *Neurotherapeutics*.
534 2022;19(1):248-62. doi: 10.1007/s13311-022-01183-1.
- 535 12. Anagnostou E. Clinical trials in autism spectrum disorder: evidence, challenges and
536 future directions. *Curr Opin Neurol*. 2018;31(2):119-25.
- 537 13. Persico AM, Ricciardello A, Lamberti M, Turriziani L, Cucinotta F, Brogna C, et al.
538 The pediatric psychopharmacology of autism spectrum disorder: A systematic review - Part I:
539 The past and the present. *Prog Neuropsychopharmacol Biol Psychiatry*. 2021;110:110326.
540 doi: <https://doi.org/10.1016/j.pnpbp.2021.110326>.

- 541 14. Edgcomb JB, Zima B. Medication Adherence Among Children and Adolescents with
542 Severe Mental Illness: A Systematic Review and Meta-Analysis. *J Child Adolesc*
543 *Psychopharmacol.* 2018;28(8):508-20. Epub 2018/07/25. doi: 10.1089/cap.2018.0040. PMID:
544 30040434.
- 545 15. Cheroni C, Caporale N, Testa G. Autism spectrum disorder at the crossroad between
546 genes and environment: contributions, convergences, and interactions in ASD developmental
547 pathophysiology. *Mol Autism.* 2020;11(1):69. doi: 10.1186/s13229-020-00370-1.
- 548 16. Jeste SS, Geschwind DH. Disentangling the heterogeneity of autism spectrum
549 disorder through genetic findings. *Nat Rev Neurol.* 2014;10(2):74-81. Epub 2014/01/29. doi:
550 10.1038/nrneurol.2013.278. PMID: 24468882.
- 551 17. Cristino L, Bisogno T, Di Marzo V. Cannabinoids and the expanded endocannabinoid
552 system in neurological disorders. *Nat Rev Neurol.* 2020;16(1):9-29. Epub 2019/12/14. doi:
553 10.1038/s41582-019-0284-z. PMID: 31831863.
- 554 18. Melis M, Greco B, Tonini R. Interplay between synaptic endocannabinoid signaling
555 and metaplasticity in neuronal circuit function and dysfunction. *Eur J Neurosci.*
556 2014;39(7):1189-201. Epub 2014/04/10. doi: 10.1111/ejn.12501. PMID: 24712998.
- 557 19. Wei D, Lee D, Cox CD, Karsten CA, Peñagarikano O, Geschwind DH, et al.
558 Endocannabinoid signaling mediates oxytocin-driven social reward. *Proc Natl Acad Sci U S*
559 *A.* 2015;112(45):14084-9. Epub 2015/10/28. doi: 10.1073/pnas.1509795112. PMID:
560 26504214.
- 561 20. Chakrabarti B, Persico A, Battista N, Maccarrone M. Endocannabinoid Signaling in
562 Autism. *Neurotherapeutics.* 2015;12(4):837-47. Epub 2015/07/29. doi: 10.1007/s13311-015-
563 0371-9. PMID: 26216231.

- 564 21. Marco EM, Laviola G. The endocannabinoid system in the regulation of emotions
565 throughout lifespan: a discussion on therapeutic perspectives. *J Psychopharmacol.*
566 2012;26(1):150-63. Epub 2011/06/23. doi: 10.1177/0269881111408459. PMID: 21693551.
- 567 22. Zou M, Li D, Li L, Wu L, Sun C. Role of the endocannabinoid system in neurological
568 disorders. *Int J Dev Neurosci.* 2019;76:95-102. Epub 2019/03/13. doi:
569 10.1016/j.ijdevneu.2019.03.002. PMID: 30858029.
- 570 23. Pietropaolo S, Marsicano G. The role of the endocannabinoid system as a therapeutic
571 target for autism spectrum disorder: Lessons from behavioral studies on mouse models.
572 *Neurosci Biobehav Rev.* 2022;132:664-78. Epub 2021/11/24. doi:
573 10.1016/j.neubiorev.2021.11.031. PMID: 34813825.
- 574 24. Zamberletti E, Gabaglio M, Woolley-Roberts M, Bingham S, Rubino T, Parolaro D.
575 Cannabidivarin Treatment Ameliorates Autism-Like Behaviors and Restores Hippocampal
576 Endocannabinoid System and Glia Alterations Induced by Prenatal Valproic Acid Exposure
577 in Rats. *Front Cell Neurosci.* 2019;13:367. Epub 2019/08/27. doi: 10.3389/fncel.2019.00367.
578 PMID: 31447649.
- 579 25. Kerr DM, Downey L, Conboy M, Finn DP, Roche M. Alterations in the
580 endocannabinoid system in the rat valproic acid model of autism. *Behav Brain Res.*
581 2013;249:124-32. Epub 2013/05/07. doi: 10.1016/j.bbr.2013.04.043. PMID: 23643692.
- 582 26. Aran A, Eylon M, Harel M, Polianski L, Nemirovski A, Tepper S, et al. Lower
583 circulating endocannabinoid levels in children with autism spectrum disorder. *Mol Autism.*
584 2019;10(1):2. doi: 10.1186/s13229-019-0256-6.

- 585 27. Karhson DS, Krasinska KM, Dallaire JA, Libove RA, Phillips JM, Chien AS, et al.
586 Plasma anandamide concentrations are lower in children with autism spectrum disorder. *Mol*
587 *Autism*. 2018;9:18. Epub 2018/03/23. doi: 10.1186/s13229-018-0203-y. PMID: 29564080.
- 588 28. Siniscalco D, Sapone A, Giordano C, Cirillo A, de Magistris L, Rossi F, et al.
589 Cannabinoid receptor type 2, but not type 1, is up-regulated in peripheral blood mononuclear
590 cells of children affected by autistic disorders. *J Autism Dev Disord*. 2013;43(11):2686-95.
591 Epub 2013/04/16. doi: 10.1007/s10803-013-1824-9. PMID: 23585028.
- 592 29. Schiavi S, Manduca A, Carbone E, Buzzelli V, Rava A, Feo A, et al. Anandamide and
593 2-arachidonoylglycerol differentially modulate autistic-like traits in a genetic model of autism
594 based on FMR1 deletion in rats. *Neuropsychopharmacology*. 2022. Epub 2022/09/17. doi:
595 10.1038/s41386-022-01454-7. PMID: 36114286.
- 596 30. Wei D, Dinh D, Lee D, Li D, Anguren A, Moreno-Sanz G, et al. Enhancement of
597 Anandamide-Mediated Endocannabinoid Signaling Corrects Autism-Related Social
598 Impairment. *Cannabis Cannabinoid Res*. 2016;1(1):81-9. Epub 2016/02/01. doi:
599 10.1089/can.2015.0008. PMID: 28861483.
- 600 31. Qin M, Zeidler Z, Moulton K, Krych L, Xia Z, Smith CB. Endocannabinoid-mediated
601 improvement on a test of aversive memory in a mouse model of fragile X syndrome. *Behav*
602 *Brain Res*. 2015;291:164-71. Epub 2015/05/17. doi: 10.1016/j.bbr.2015.05.003. PMID:
603 25979787.
- 604 32. Arnold JC, McCartney D, Suraev A, McGregor IS. The safety and efficacy of low
605 oral doses of cannabidiol: An evaluation of the evidence. *Clinical and translational science*.
606 2023;16(1):10-30.

- 607 33. Chesney E, Oliver D, Green A, Sovi S, Wilson J, Englund A, et al. Adverse effects of
608 cannabidiol: a systematic review and meta-analysis of randomized clinical trials.
609 Neuropsychopharmacology. 2020;45(11):1799-806. Epub 2020/04/09. doi: 10.1038/s41386-
610 020-0667-2. PMID: 32268347.
- 611 34. Larsen C, Shahinas J. Dosage, Efficacy and Safety of Cannabidiol Administration in
612 Adults: A Systematic Review of Human Trials. J Clin Med Res. 2020;12(3):129-41. Epub
613 2020/04/02. doi: 10.14740/jocmr4090. PMID: 32231748.
- 614 35. Reuveni N, Carlson CA, Schwartz S, Meter D, Barrett TS, Freeman SM. The
615 antidepressant and anxiolytic effects of cannabinoids in chronic unpredictable stress: a
616 preclinical systematic review and meta-analysis. Transl Psychiatry. 2022;12(1):217. Epub
617 2022/06/01. doi: 10.1038/s41398-022-01967-1. PMID: 35641487.
- 618 36. Graczyk M, Lewandowska AA, Dzierżanowski T. The Therapeutic Potential of
619 Cannabis in Counteracting Oxidative Stress and Inflammation. Molecules. 2021;26(15). doi:
620 10.3390/molecules26154551. PMID: 34361704.
- 621 37. Soliman N, Haroutounian S, Hohmann AG, Krane E, Liao J, Macleod M, et al.
622 Systematic review and meta-analysis of cannabinoids, cannabis-based medicines, and
623 endocannabinoid system modulators tested for antinociceptive effects in animal models of
624 injury-related or pathological persistent pain. Pain. 2021;162(Suppl 1):S26-s44. doi:
625 10.1097/j.pain.0000000000002269. PMID: 33729209.
- 626 38. Zavala-Tecuapetla C, Luna-Munguia H, López-Meraz ML, Cuellar-Herrera M.
627 Advances and Challenges of Cannabidiol as an Anti-Seizure Strategy: Preclinical Evidence.
628 Int J Mol Sci. 2022;23(24). doi: 10.3390/ijms232416181. PMID: 36555823.

- 629 39. Esposito G, Pesce M, Seguella L, Sanseverino W, Lu J, Corpetti C, et al. The
630 potential of cannabidiol in the COVID-19 pandemic. *Br J Pharmacol.* 2020;177(21):4967-70.
631 doi: 10.1111/bph.15157. PMID: 32519753.
- 632 40. Tadijan A, Vlašić I, Vlainić J, Đikić D, Oršolić N, Jazvinščak Jembrek M.
633 Intracellular Molecular Targets and Signaling Pathways Involved in Antioxidative and
634 Neuroprotective Effects of Cannabinoids in Neurodegenerative Conditions. *Antioxidants*
635 [Internet]. 2022; 11(10).
- 636 41. Stohs SJ, Ray SD. Is cannabidiol hepatotoxic or hepatoprotective: A review. *Toxicol*
637 *Res Appl.* 2020;4:2397847320922944. doi: 10.1177/2397847320922944.
- 638 42. Russo EB. The Case for the Entourage Effect and Conventional Breeding of Clinical
639 Cannabis: No "Strain," No Gain. *Front Plant Sci.* 2018;9:1969. doi: 10.3389/fpls.2018.01969.
640 PMID: 30687364.
- 641 43. Russo EB, McPartland JM. Cannabis is more than simply delta(9)-
642 tetrahydrocannabinol. *Psychopharmacology (Berl).* 2003;165(4):431-2; author reply 3-4. doi:
643 10.1007/s00213-002-1348-z. PMID: 12491031.
- 644 44. Ben-Shabat S, Fride E, Sheskin T, Tamiri T, Rhee MH, Vogel Z, et al. An entourage
645 effect: inactive endogenous fatty acid glycerol esters enhance 2-arachidonoyl-glycerol
646 cannabinoid activity. *Eur J Pharmacol.* 1998;353(1):23-31. doi: 10.1016/s0014-
647 2999(98)00392-6. PMID: 9721036.
- 648 45. Johnson JR, Burnell-Nugent M, Lossignol D, Ganæ-Motan ED, Potts R, Fallon MT.
649 Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the
650 efficacy, safety, and tolerability of THC:CBD extract and THC extract in patients with

- 651 intractable cancer-related pain. *J Pain Symptom Manage.* 2010;39(2):167-79. Epub
652 2009/11/10. doi: 10.1016/j.jpainsymman.2009.06.008. PMID: 19896326.
- 653 46. Pamplona FA, da Silva LR, Coan AC. Potential Clinical Benefits of CBD-Rich
654 Cannabis Extracts Over Purified CBD in Treatment-Resistant Epilepsy: Observational Data
655 Meta-analysis. *Front Neurol.* 2018;9:759. Epub 2018/09/28. doi: 10.3389/fneur.2018.00759.
656 PMID: 30258398.
- 657 47. Shalev N, Kendall M, Anil SM, Tiwari S, Peeri H, Kumar N, et al. Phytocannabinoid
658 Compositions from Cannabis Act Synergistically with PARP1 Inhibitor against Ovarian
659 Cancer Cells In Vitro and Affect the Wnt Signaling Pathway. *Molecules.* 2022;27(21). Epub
660 2022/11/12. doi: 10.3390/molecules27217523. PMID: 36364346.
- 661 48. Anis O, Vinayaka AC, Shalev N, Namdar D, Nadarajan S, Anil SM, et al. Cannabis-
662 Derived Compounds Cannabichromene and Δ^9 -Tetrahydrocannabinol Interact and Exhibit
663 Cytotoxic Activity against Urothelial Cell Carcinoma Correlated with Inhibition of Cell
664 Migration and Cytoskeleton Organization. *Molecules.* 2021;26(2). Epub 2021/01/23. doi:
665 10.3390/molecules26020465. PMID: 33477303.
- 666 49. Blasco-Benito S, Seijo-Vila M, Caro-Villalobos M, Tundidor I, Andradas C, García-
667 Taboada E, et al. Appraising the "entourage effect": Antitumor action of a pure cannabinoid
668 versus a botanical drug preparation in preclinical models of breast cancer. *Biochem*
669 *Pharmacol.* 2018;157:285-93. Epub 2018/06/26. doi: 10.1016/j.bcp.2018.06.025. PMID:
670 29940172.
- 671 50. Bonn-Miller MO, ElSohly MA, Loflin MJE, Chandra S, Vandrey R. Cannabis and
672 cannabinoid drug development: evaluating botanical versus single molecule approaches. *Int*

- 673 Rev Psychiatry. 2018;30(3):277-84. doi: 10.1080/09540261.2018.1474730. PMID:
674 30179534.
- 675 51. Rice LJ, Cannon L, Dadlani N, Cheung MMY, Einfeld SL, Efron D, et al. Efficacy of
676 cannabinoids in neurodevelopmental and neuropsychiatric disorders among children and
677 adolescents: a systematic review. *European Child & Adolescent Psychiatry*. 2023:1-22.
- 678 52. Aran A, Cassuto H, Lubotzky A, Wattad N, Hazan E. Brief report: cannabidiol-rich
679 cannabis in children with autism spectrum disorder and severe behavioral problems—a
680 retrospective feasibility study. *Journal of Autism and Developmental Disorders*.
681 2019;49(3):1284-8.
- 682 53. Barchel D, Stolar O, De-Haan T, Ziv-Baran T, Saban N, Fuchs DO, et al. Oral
683 Cannabidiol Use in Children With Autism Spectrum Disorder to Treat Related Symptoms
684 and Co-morbidities. *Front Pharmacol*. 2019;9:1521. doi: 10.3389/fphar.2018.01521. PMID:
685 30687090.
- 686 54. Bar-Lev Schleider L, Mechoulam R, Saban N, Meiri G, Novack V. Real life
687 experience of medical cannabis treatment in autism: analysis of safety and efficacy. *Scientific*
688 *reports*. 2019;9(1):1-7.
- 689 55. Fleury-Teixeira P, Caixeta FV, Ramires da Silva LC, Brasil-Neto JP, Malcher-Lopes
690 R. Effects of CBD-Enriched Cannabis sativa Extract on Autism Spectrum Disorder
691 Symptoms: An Observational Study of 18 Participants Undergoing Compassionate Use.
692 *Front Neurol*. 2019;10:1145. Epub 2019/11/19. doi: 10.3389/fneur.2019.01145. PMID:
693 31736860.

- 694 56. Bilge S, Ekici B. CBD-enriched cannabis for autism spectrum disorder: an experience
695 of a single center in Turkey and reviews of the literature. *J Cannabis Res.* 2021;3(1):53. Epub
696 2021/12/17. doi: 10.1186/s42238-021-00108-7. PMID: 34911567.
- 697 57. Hacoen M, Stolar OE, Berkovitch M, Elkana O, Kohn E, Hazan A, et al. Children
698 and adolescents with ASD treated with CBD-rich cannabis exhibit significant improvements
699 particularly in social symptoms: an open label study. *Translational Psychiatry.*
700 2022;12(1):375.
- 701 58. Aran A, Harel M, Cassuto H, Polyansky L, Schnapp A, Wattad N, et al. Cannabinoid
702 treatment for autism: a proof-of-concept randomized trial. *Molecular autism.* 2021;12(1):1-
703 11.
- 704 59. da Silva Junior EA, Medeiros WMB, Dos Santos JPM, de Sousa JMM, da Costa FB,
705 Pontes KM, et al. Evaluation of the efficacy and safety of cannabidiol-rich cannabis extract in
706 children with autism spectrum disorder: randomized, double-blind and controlled placebo
707 clinical trial. *Trends in Psychiatry and Psychotherapy.* 2022;(AheadOfPrint):0-.
- 708 60. Schnapp A, Harel M, Cayam-Rand D, Cassuto H, Polyansky L, Aran A. A Placebo-
709 Controlled Trial of Cannabinoid Treatment for Disruptive Behavior in Children and
710 Adolescents with Autism Spectrum Disorder: Effects on Sleep Parameters as Measured by
711 the CSHQ. *Biomedicines.* 2022;10(7):1685.
- 712 61. Lord C, Rutter M, DiLavore P, Risi S, Gotham K, Bishop S, et al. Autism Diagnostic
713 Observation Schedule: ADOS-2| Pearson Assessment. Pearson. ; 2012.
- 714 62. Lattanzi S, Brigo F, Trinkka E, Zaccara G, Cagnetti C, Del Giovane C, et al. Efficacy
715 and Safety of Cannabidiol in Epilepsy: A Systematic Review and Meta-Analysis. *Drugs.*

- 716 2018;78(17):1791-804. Epub 2018/11/06. doi: 10.1007/s40265-018-0992-5. PMID:
717 30390221.
- 718 63. Stockings E, Zagic D, Campbell G, Weier M, Hall WD, Nielsen S, et al. Evidence for
719 cannabis and cannabinoids for epilepsy: a systematic review of controlled and observational
720 evidence. *J Neurol Neurosurg Psychiatry*. 2018;89(7):741-53. Epub 2018/03/08. doi:
721 10.1136/jnnp-2017-317168. PMID: 29511052.
- 722 64. Devinsky O, Cross JH, Wright S. Trial of Cannabidiol for Drug-Resistant Seizures in
723 the Dravet Syndrome. *N Engl J Med*. 2017;377(7):699-700. doi: 10.1056/NEJMc1708349.
724 PMID: 28813226.
- 725 65. Busner J, Targum SD. The clinical global impressions scale: applying a research tool
726 in clinical practice. *Psychiatry (Edgmont)*. 2007;4(7):28-37. PMID: 20526405.
- 727 66. Rodgers J, Wigham S, McConachie H, Freeston M, Honey E, Parr JR. Development
728 of the anxiety scale for children with autism spectrum disorder (ASC-ASD). *Autism Res*.
729 2016;9(11):1205-15.
- 730 67. Bruni O, Ottaviano S, Guidetti V, Romoli M, Innocenzi M, Cortesi F, et al. The Sleep
731 Disturbance Scale for Children (SDSC). Construction and validation of an instrument to
732 evaluate sleep disturbances in childhood and adolescence. *J Sleep Res*. 1996;5(4):251-61.
733 doi: 10.1111/j.1365-2869.1996.00251.x. PMID: 9065877.
- 734 68. Efron D, Freeman JL, Cranswick N, Payne JM, Mulraney M, Prakash C, et al. A pilot
735 randomised placebo-controlled trial of cannabidiol to reduce severe behavioural problems in
736 children and adolescents with intellectual disability. *British Journal of Clinical
737 Pharmacology*. 2021;87(2):436-46.

738 69. Chen H, Yang T, Chen J, Chen L, Dai Y, Zhang J, et al. Sleep problems in children
739 with autism spectrum disorder: a multicenter survey. *BMC Psychiatry*. 2021;21(1):406. Epub
740 2021/08/18. doi: 10.1186/s12888-021-03405-w. PMID: 34399715.

741 70. Malow BA, Katz T, Reynolds AM, Shui A, Carno M, Connolly HV, et al. Sleep
742 Difficulties and Medications in Children With Autism Spectrum Disorders: A Registry Study.
743 *Pediatrics*. 2016;137 Suppl 2:S98-s104. Epub 2016/02/26. doi: 10.1542/peds.2015-2851H.
744 PMID: 26908483.

745 71. Stolar O, Hazan A, Vissoker RE, Kishk IA, Barchel D, Lezinger M, et al. Medical
746 cannabis for the treatment of comorbid symptoms in children with autism spectrum disorder:
747 An interim analysis of biochemical safety. *Front Pharmacol*. 2022;13:977484. Epub
748 2022/10/18. doi: 10.3389/fphar.2022.977484. PMID: 36249785.

749 72. Silva EADJ, Medeiros WMB, Torro N, Sousa JMM, Almeida I, Costa FBD, et al.
750 Cannabis and cannabinoid use in autism spectrum disorder: a systematic review. *Trends*
751 *Psychiatry Psychother*. 2022;44:e20200149. Epub 2021/05/28. doi: 10.47626/2237-6089-
752 2020-0149. PMID: 34043900.

753 73. Kalvin CB, Marsh CL, Ibrahim K, Gladstone TR, Woodward D, Grantz H, et al.
754 Discrepancies between parent and child ratings of anxiety in children with autism spectrum
755 disorder. *Autism Res*. 2020;13(1):93-103. Epub 2019/10/24. doi: 10.1002/aur.2220. PMID:
756 31643143.


757

758 **Figure Legend**

759 **Fig 1. Clinical Global Impression – Global Improvement.**

760 **Fig 2. Clinical Global Impression – Severity of Illness.**

761 **Fig 3. Clinical Global Impression - Therapeutic Effect after 28 days of treatment.**




Figure

GLOBAL IMPROVEMENT RATINGS

1. Very much improved
2. Much improved
3. Minimally improved
4. No change

Figure



EFFICACY INDEX SCORES

2 = Marked Therapeutic Effect, Vast improvement. Complete or nearly complete remission of all symptoms.

Side Effects: Do not significantly interfere with patient's functioning.

5 = Moderate Therapeutic Effect, Decided improvement. Partial remission of symptoms.

Side Effects: None.

6 = Moderate Therapeutic Effect, Decided improvement. Partial remission of symptoms.

Side Effects: Do not significantly interfere with patient's functioning.

9 = Minimal Therapeutic Effect, Slight improvement which doesn't alter status of care of patient.

Side Effects: None.

13 = Unchanged or worse.

Side effects: None.